News Archives

May 1, 2005

1995 - 2005
VersaPharm Celebrates 10th Anniversary

VersaPharm has a ten-year track record of providing outstanding product value with caring and professional service. Thank you to each person who has been a part of our ten year history.

April 15, 2005

Additional Unit Dose Packaging
In Response to Customer Requests

VersaPharm has increased the number of products available in Unit Dose 10x10 blister packs. Acute and long term care, as well as correctional facilities, have found Unit Dose packaging to be flexible, convenient and more economical. VersaPharm provides more package sizes and styles from Bulk to Unit of Use and Unit Dose to meet customer needs.

May 10, 2004

Ethosuximide Oral Solution, USP
Now Available

VersaPharm is pleased to announce that Ethosuximide Oral Solution, USP has been approved by the FDA and is now being shipped. Ethosuximide Oral Solution is equivalent to Zarontin (TM) by Parke Davis. Zarontin is indicated for the control of absence (petit Mal) epilepsy.

February 11, 2004

VersaPharm Announces
Hemophilia Camp Scholarship Awards

VersaPharm Incorporated announced winners of the VersaPharm Hemophilia Camp Scholarship Awards today. Winners were drawn from entries made at the NHF 55^th Annual Meeting held in Salt Lake City in November 2003. Winners were chosen in two categories: children and Medical Professionals.

Recipients of the award in the children’s category received $250 for tuition to the Hemophilia Camp of their choice. Winners include:

· Tori Echeverria of Winnemucca, NV
Tori’s camp of choice is Hemophilia Foundation of Nevada’s Camp Independence, located in Las Vegas.

The winner in the Medical Professional category received a $250 donation to the camp of his or her choice. The winner of the medical professional category is:

· Christy Humphrey of Hemophilia of Georgia located in Atlanta, GA
Ms. Humphrey’s camp of choice is Camp Wannaklot located in Rutledge, Georgia.

VersaPharm’s Aminocaproic Acid Tablets and Oral Solution are used in the treatment of hemophilia and other bleeding disorders.

“It’s part of the VersaPharm mission to give back to the community,” said Carl Merideth, Vice president of Sales and Marketing for VersaPharm. “Investing in our children is one of the most important things we can do.”

September 30, 2003

Track Your Shipment Online:
VersaPharm UPS Order Tracking

VersaPharm Incorporated's new Website feature allows you to check on your shipment using your purchase order number. The page links with United Parcel Service's Database and provides you a quick status report on your shipment. Just click on "Order Tracking."

October 18, 2001

NEWS

The Food and Drug Administration
An Agency of the U.S. Department of Health and Human Services

October 18, 2001	Print Media: 301-827-6242
	Broadcast Media: 301-827-3434
	Consumer Inquiries: 888-INFO-FDA

The Food and Drug Administration today issued the following Public Health Advisory:

FDA PUBLIC HEALTH ADVISORY:
UPDATE ON USE OF DOXYCYCLINE FOR ANTHRAX EXPOSURE

Secretary of Health and Human Services Tommy G. Thompson announced on October 17 in testimony before the Committee on Governmental Affairs and Subcommittee on International Security, Proliferation and Federal Services of the United States Senate, that the Food and Drug Administration is approving new labeling for the use of several antibiotics to treat anthrax.

The following is being issued to provide healthcare providers with clarification on dosing regimens about doxycycline. In addition, FDA is developing more information about the use of this and other antibiotics to treat anthrax and will provide this information soon.

Doxycycline is approved for the treatment of anthrax in all its forms. The FDA is providing additional information concerning the dosing regimen for the treatment of anthrax, including cutaneous and inhalation anthrax (post-exposure). The currently recommended dosage regimen of doxycycline for severe disease is 100 mg every 12 hours for adults and 1mg per pound (2.2mg per kilogram) every 12 hours for children less than 100 pounds. These dosage regimens are appropriate for use in patients who have been exposed to anthrax (Bacillus anthracis) regardless of the route of exposure.

FDA and other health authorities strongly discourage individuals from taking any antibiotic for prevention of anthrax without the specific advice of a physician and a clear indication that exposure to the organism may have occurred. FDA News Page

August 15, 2001

VersaPharm Partners
With Project Hope

VersaPharm Incorporated has donated 400,000 Ethambutol tablets through Project Hope to the Republic of Uzbekistan for use in the battle against Tuberculosis. The Uzbekistan Ministry of Health has confirmed to VersaPharm that the pharmaceuticals will be used as part of the DOTS (Directly Observed Therapy) program for TB elimination to the area’s 15 million residents. Project Hope provides land-based health care education and approximately $100 million worth of resources to more than two dozen countries each year although they are best known for the S.S. Hope, the world’s first peacetime hospital ship. www.projecthope.org

May 18, 2001

VersaPharm Platinum Sponsor of
Feed the Hungry Golf Tournament

Feed the Hungry Foundation’s 18^th Annual Golf Tournament and largest fund raising event was held on May 1st in Acworth, GA. The tournament brought in $19,000 for the Foundation’s Mission as an emergency food resource for people in the City of Atlanta and the surrounding counties. Sponsors included Lead Sponsor Jenny Pruitt & Associates and other Platinum and Gold Sponsors.

http://www.e-christ.org/feedthehungry/

May 3, 2001

VersaPharm Goes Online

NEWS RELEASE
For Immediate Release

Contact: Carl Merideth, Vice President
Sales/Marketing 770-499-8100
merideth@versapharm.com

The President of VersaPharm Incorporated, R. Joe Ware, today announced the launch of VersaPharm.com on the World Wide Web. The Marietta, Georgia based pharmaceutical company provides cost-effective generic alternative products to underserved markets. They have “accomplished a major goal in making VersaPharm's products and services available 24-hours a day on the new website,” he said.

VersaPharm specializes in the development and marketing of specialty prescription products to be used in the treatment of certain blood disorders, including tuberculosis and hemophilia. The firm created the website not only to provide information via the Internet, but also to allow Authorized Purchasers to buy FDA approved products online.

Mr. Ware said “VersaPharm's goal was to make it easier for patients and health care professional to access information on current therapies, available products, and other resources that will enhance successful treatment outcomes. Although it has taken several months to develop and launch the website, we expect to add new features and additional content on a regular basis.”

Carl Merideth, Vice President Sales and Marketing, explained the website includes product photographs as well as close-up photographs of each type of tablet and capsule for quick identification of VersaPharm products. The site will feature new product announcements, package insert information, and links to other related products.

“As a people-oriented business, we have been excited about developing websites for our customers,” Merideth said. “Just by using the Internet, they can get information easier and faster, without cost, day or night. Now, when customers call to ask how they can get certain information, we are able to tell them, ‘It’s on the website.’ They will find more than fifty pages of helpful information on this website plus links to other websites.”

VersaPharm worked with Darrell Thompson of Photel International for the development and design of multiple websites for the company and its products. Mini-websites were established for eight different product names and two treatment areas: Tuberculosis at tbmeds.com and Hemophilia at hemophiliameds.com. These ten mini-websites are linked to the corporate website, www.versapharm.com, which provides detailed information about each of the products, the company’s management team, corporate policies and how it is now easier to do business with VersaPharm.

May 3, 2001

Rifampin Capsules Now Available

Rifampin Capsules, USP by VersaPharm has recently been approved by the FDA and is now being shipped. The Rifampin entry completes the list of the four key antitubercular products used to eradicate TB. VersaPharm already provides Isoniazid, Pyrazinamide, and Ethambutol throughout the United States.

February 19, 2003

Aminocaproic Acid

New Name:
Oral Solution USP 25%

New Packaging:
From Glass to Plastic

New Package:
Entry level 237 mL Size
For Lower Inventory Cost

Now Available in two sizes, 237 & 473 mL,
plastic HDPE bottles with Child Resistant Closure (CRC)

News Release

January 17, 2001

New Corporate Headquarters

VersaPharm Incorporated today announced the company's move into new corporate offices in Marietta, Georgia. President R. Joe Ware said, "The new facilities provided more office space to handle the company's growth, improved use of technology and additional warehouse space to handle new products."

Located in West Oak Commons office park only a few miles from the old offices, VersaPharm is easily reached off I-75 north of Atlanta. The new address is 1775 West Oak Parkway, Suite 800, Marietta, GA 30062-2260.

FDA PUBLIC HEALTH ADVISORY: UPDATE ON USE OF DOXYCYCLINE FOR ANTHRAX EXPOSURE

FDA PUBLIC HEALTH ADVISORY:
UPDATE ON USE OF DOXYCYCLINE FOR ANTHRAX EXPOSURE